European journal of medicinal chemistry
Cure8 research brief
Why This Matters
The study identifies HK2 inhibition as a potential mechanism to shift pro-inflammatory macrophages and reduce intestinal inflammation in preclinical models, which could guide future drug development for IBD.
Who Should Pay Attention
Researchers, translational scientists, drug developers, and clinicians interested in IBD immunometabolism and novel anti-inflammatory therapeutics.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is a preclinical drug-discovery study published as an abstract/full-text in a medicinal chemistry journal. Lab experiments identified ZSW as a potent HK2 inhibitor (reported IC50 ~0.48 μM) and used molecular docking and probe pull-down to support target engagement.
Cellular work linked HK2 inhibition to decreased glycolysis in macrophages and reduced NF-κB nuclear translocation. Mouse experiments are described as showing improved intestinal inflammatory state with ZSW treatment. The work is early-stage: findings are laboratory and animal data only, not clinical trials.
If you see interest in HK2-targeting approaches, this provides a mechanistic rationale but does not mean a safe or effective treatment for people yet.
Keep In Mind
This is a preclinical medicinal chemistry and mechanistic study (cellular assays and mouse models). Results do not imply safety or effectiveness in humans; further pharmacology, toxicology, and clinical testing would be needed.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationEuropean journal of medicinal chemistry
AuthorsYawei Han, Guangyuan Liu, Huimin Yuan +10 more
InstitutionHubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, No. 13 Hangkong Road, Wuhan, 430030, China.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedMay 5, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Suppressing FUT8 with a Novel Small Molecule Inhibitor Ameliorates Inflammation in Murine T Cell-mediated Colitis Models.
This study identifies FUT8, an enzyme that adds core fucose to N-glycans, as a possible new target to reduce pro-inflammatory T-cell responses in IBD. For people with IBD, new mechanisms in preclinical research may...
From discovery to mechanism: novel anti-ulcerative colitis meroterpenoids act through the PI3K/IκB-α/MAPK pathway.
The study reports a newly discovered class of marine-derived meroterpenoids and identifies a lead compound that reduced inflammatory markers and improved colitis in mice, which could eventually inform new drug...
Modulating immune toxicity in ulcerative colitis using a small molecule RAB27A inhibitor
The report describes a novel small-molecule inhibitor (IMYX-3) targeting RAB27A to reduce neutrophil-mediated damage in ulcerative colitis models, which could point to a new therapeutic approach if later validated in...